Alumis Announces Merger With ACELYRIN
February 17, 2025
February 17, 2025
SAN FRANCISCO, California, Feb. 17 -- Cooley, a law firm, issued the following news release:
Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.
Upon the close of the transaction, Alumis and ACELYRIN stockhol . . .
Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.
Upon the close of the transaction, Alumis and ACELYRIN stockhol . . .